AELIS.PA stock down 6.16% to €1.37 pre-market on EURONEXT: model flags €3.06 fair value

AELIS.PA stock opened the pre-market session down 6.16% at €1.37 on EURONEXT after an early sell-off from an opening price of €1.46. Trading volume is elevated at 109,766 shares versus an average of 59,784, suggesting heavier interest. Investors are watching clinical-readout timing and cash runway for the Bordeaux-based biotech while sector weakness in Healthcare also weighs on performance.

AELIS.PA stock: price action and key intraday metrics

The immediate move is clear: AELIS.PA stock slipped €0.09, or -6.16%, to €1.37 in pre-market trades. The stock traded between a day low of €1.32 and a day high of €1.47, with a 52-week range of €0.67 to €2.46. Volume at 109,766 shares is roughly 1.84x the 50-day average, signaling above-normal trading interest.

AELIS.PA stock: fundamentals and valuation snapshot

Aelis Farma (AELIS.PA) reports EPS of -€0.64 and a reported PE of -2.14, reflecting ongoing losses. Market capitalisation is about €18,676,172 and shares outstanding are 13,632,242. Key ratios show price-to-book of 3.06, price-to-sales of 8.01, current ratio 3.18, and debt-to-equity 1.13, which together imply a stretched valuation for a small-cap biotech with negative earnings.

AELIS.PA stock: clinical pipeline and news drivers

The company is developing CB1 signaling-specific inhibitors including AEF0117 in Phase 2b and AEF0217 after Phase 1 results. Clinical timing and trial readouts remain the primary catalysts for AELIS.PA stock. Sector headlines and comparator moves can amplify volatility; see recent biotech coverage on Investing.com for broader comparisons and sector context source.

AELIS.PA stock: technical setup and trading signals

Momentum indicators are mixed: RSI at 59.40 suggests room before overbought territory, MACD histogram is slightly positive, and CCI reads 117.62, indicating short-term strength despite today’s drop. The 50-day average is €1.21 and the 200-day average is €1.17, putting the current price above both, which historically supports short-term buyers.

Meyka AI grade and AELIS.PA stock analysis

Meyka AI rates AELIS.PA with a score of 64.76 out of 100 and assigns a B: HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The internal grade balances positive liquidity metrics—cash per share €0.79 and current ratio 3.18—against negative profitability and a high price-to-sales ratio. These grades are informational and not financial advice.

AELIS.PA stock: risks, sector context and investor considerations

Key risks for AELIS.PA stock include trial delays, binary clinical outcomes, and rising debt (debt/equity 1.13). The Healthcare sector average P/E is about 34.32, higher than AELIS.PA’s current metrics but reflecting larger, profitable peers. Small-cap biotech volatility and low free-cash-flow yield require careful position sizing and risk controls for investors looking at AELIS.PA investment ideas.

Final Thoughts

AELIS.PA stock is trading down 6.16% pre-market at €1.37 on EURONEXT with above-average volume, driven by biotech sector sensitivity and company-specific catalyst timing. Meyka AI’s forecast model projects a 12-month fair value near €3.06, implying an upside of 123.36% versus the current price. That projection contrasts with short-term technical weakness and negative EPS (-€0.64), so investors face a trade-off between high upside potential and binary clinical risk. Our view: monitor upcoming clinical milestones and cash-burn updates before adding exposure. For continuous monitoring see AELIS.PA on Meyka AI’s platform for real-time signals and sector comparisons AELIS.PA on Meyka. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.